RCS - ReNeuron Group plc - Positive iPSC data presented at conference

ReNeuronAnnouncement

08/12/2022 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221208:nRSH9871Ia&default-theme=true

RNS Number : 9871I  ReNeuron Group plc  08 December 2022

 
ReNeuron Group plc

("ReNeuron" or the "Company")

 

Positive induced pluripotent stem cell data presented at industry conference

 

ReNeuron presents new data highlighting the advantages of its novel type of
iPSCs including data

from the Company's collaboration with University College London

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived
exosomes technologies, announces that one of its lead scientists, Dr Steve
Pells, yesterday presented new data on the advantages of its induced
pluripotent stem cells (iPSCs) including data from the Company's collaboration
with University College London (UCL), at a major industry conference on
iPSC-Derived Cell Therapies.

 

Key highlights from the presentation entitled Conditionally Immortalised
iPSCs: A New Approach to Off-the-Shelf Allogeneic iPSC-Derived Cell Therapies
included:

 

·    Data was presented on the benefits of ReNeuron's novel type of iPSCs,
known as Conditionally Immortalised Induced Pluripotent Stem Cells (CI-iPSCs)

·    CI-iPSCs can differentiate into any cell type found in the human
body, however unlike classical iPSCs, the addition of the conditional
immortalisation technology gives greater control of the growth and survival of
the subsequent differentiated cells, making them easier to grow in large
quantities, purify and bank

·    Data was presented highlighting how the use of CI-iPSCs lead to the
manufacture of stable Schwann cells for the treatment of peripheral nerve
damage repair

·    This feature of CI-iPSCs also provides the ideal pluripotent stem
cell line for the development of "off the shelf" stem cell-based therapies
with work ongoing at UCL

 

The presentation will be available shortly on the Company's website:
https://www.reneuron.com/investors/presentations/
(https://www.reneuron.com/investors/presentations/)

 

Dr Randolph Corteling, Chief Scientific Officer, commented: "The data
presented yesterday really highlights the potential for the use of ReNeuron's
proprietary conditionally immortalised iPSCs in the treatment of peripheral
nerve damage repair and the development of "off the shelf" stem cell-based
therapies. Additionally, our CI-iPSCs are a key enabling technology for the
expansion of the Company's CustomEx(TM) exosome platform that allows growth
beyond ReNeuron's current seven distinct exosome producing stem cell lines,
therefore offering further ability to customise the exosome cell type for
partners' needs and the payload / target cell of their choice."

 

CustomEx(TM) is a register trademark of ReNeuron Limited

 

 
ENDS

 

Contacts:

 

 ReNeuron                                      www.reneuron.com/investors (http://www.reneuron.com/investors)
 Catherine Isted, Chief Executive Officer      Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Walbrook PR (Media & Investor Relations)      +44 (0)20 7933 8780 or reneuron@walbrookpr.com
 Alice Woodings / Paul McManus                 +44 (0)7407 804 654 / +44 (0)7980 541 893

 

 

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell derived Exosome Technologies
company, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.

 

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Company has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.

 

The Company has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATRBBTMTIMTBT